Barclays PLC Acquires 5,229 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX)

Barclays PLC lifted its stake in MoonLake Immunotherapeutics (NASDAQ:MLTX) by 1,269.2% in the third quarter, Holdings Channel.com reports. The fund owned 5,641 shares of the company’s stock after purchasing an additional 5,229 shares during the period. Barclays PLC’s holdings in MoonLake Immunotherapeutics were worth $283,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently made changes to their positions in the stock. FMR LLC boosted its holdings in shares of MoonLake Immunotherapeutics by 35.8% in the third quarter. FMR LLC now owns 4,950,224 shares of the company’s stock worth $249,590,000 after acquiring an additional 1,306,215 shares during the period. Avoro Capital Advisors LLC raised its position in shares of MoonLake Immunotherapeutics by 7.4% in the second quarter. Avoro Capital Advisors LLC now owns 2,770,000 shares of the company’s stock worth $121,797,000 after buying an additional 190,000 shares in the last quarter. Westfield Capital Management Co. LP raised its position in shares of MoonLake Immunotherapeutics by 4.4% in the third quarter. Westfield Capital Management Co. LP now owns 1,167,358 shares of the company’s stock worth $58,858,000 after buying an additional 49,733 shares in the last quarter. Federated Hermes Inc. raised its position in shares of MoonLake Immunotherapeutics by 2.6% in the second quarter. Federated Hermes Inc. now owns 1,128,428 shares of the company’s stock worth $49,617,000 after buying an additional 28,672 shares in the last quarter. Finally, Marshall Wace LLP raised its position in shares of MoonLake Immunotherapeutics by 115.0% in the second quarter. Marshall Wace LLP now owns 1,098,630 shares of the company’s stock worth $48,307,000 after buying an additional 587,684 shares in the last quarter. 93.85% of the stock is owned by institutional investors.

MoonLake Immunotherapeutics Price Performance

NASDAQ MLTX opened at $53.45 on Monday. The stock has a market capitalization of $3.42 billion, a PE ratio of -41.43 and a beta of 1.31. MoonLake Immunotherapeutics has a 1 year low of $37.55 and a 1 year high of $64.98. The business’s 50-day moving average is $52.01 and its 200 day moving average is $48.57.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last posted its earnings results on Thursday, November 7th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.12). During the same period in the prior year, the company earned ($0.18) earnings per share. As a group, equities research analysts anticipate that MoonLake Immunotherapeutics will post -1.75 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of MoonLake Immunotherapeutics in a research report on Monday, September 23rd. Needham & Company LLC restated a “buy” rating and set a $62.00 price target on shares of MoonLake Immunotherapeutics in a research report on Thursday, September 12th. Wedbush restated an “outperform” rating and set a $73.00 price target (down previously from $92.00) on shares of MoonLake Immunotherapeutics in a research report on Tuesday, November 5th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $100.00 price objective on shares of MoonLake Immunotherapeutics in a research note on Thursday, November 14th. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, MoonLake Immunotherapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $81.43.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.